Dysport – pharmaceutical daily

September 27, 2019 Off

Ipsen gets FDA approval of Dysport for treatment of Upper Limb Spasticity in children, excluding cerebral palsy

Ipsen got approval for Dysport, the first and only FDA-approved botulinum toxin for treatment of both pediatric upper and lower limb spasticity, as the pivotal Phase 3 study showed Dysport improved spasticity symptoms in children aged two to 17 experiencing upper limb spasticity, as measured by the primary efficacy endpoint of Modified Ashworth Scale at elbow or wrist flexors at Week 6.

September 23, 2019 Off

Ipsen’s study of Dysport shows improving outcomes of patients living with spastic paresis

By BusinessWire

Ipsen’s study of Dysport treatment of patients with personalized diary-based rehabilitation program improved patients’ voluntary movement as measured by a composite active range of motion (CXA) outcome.

January 11, 2019 Off

Ipsen’s Dysport to treat a range of therapeutic indications

By Dino Mustafić

Ipsen has presented results of Dysport and botulinum toxins pipeline, from basic science to clinical phases, and patients and caregivers surveys, highlighting differentiation of Dysport in the treatment of spasticity and movement disorders.